fashion -WSS

fashion

author：entertainment 2025-10-01 07:41:03 - browse：24

Eli Lilly headquarters — Kristoffer Tripplaar/AP

Eventually, the luckiest companies get to deal with a very particular problem: what to do when their stock could be getting ahead of itself.

It’s a problem Eli Lilly got a little taste of Tuesday when it announced its full-year earnings. The drugmaker’s stock has more than doubled over the past 12 months due to the ever-increasing hopes for its GLP-1-based diabetes and weight loss drug, sold under the brand names Mounjaro and Zepbound. It was a big deal when Lilly became the first drug company ever to have a market value of $500 billion; it’s now sitting at a stunning $670 billion.

At first, the earnings report suggested the company had blasted through expectations again, announcing fourth-quarter 2023 sales of $9.35 billion, almost half a billion dollars above analysts’ expectations, and also announcing new data for Mounjaro in treating metabolic dysfunction-associated steatohepatitis (MASH), a form of liver disease previously called NASH. Initially, shares traded up 5%.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Cancer drug shortages should be causing more outrage
Next article： President Biden's budget: Here's what you might have missed

focus

leisure time

WSS

Readout Newsletter: Acadia, Eli Lilly, Madrigal Pharma updates

Change Healthcare cyberattack prompts Medicare loan program

Amylyx ALS drug fails trial: Relyvrio patients react with fear, worry

First medicine developed to treat MASH expected to be approved soon

EPA limits use of carcinogenic gas for sterilizing medical devices

In surprise move, FDA calls for advisory committee on Lilly's Alzheimer's drug

hotspot

fashion

hotspot

Apple is now the first public company to be valued at $3 trillion

Why depression after traumatic brain injury is distinct

Cancer drug shortages should be causing more outrage

Readout LOUD podcast: ALS dilemma, first MASH drug, and more

How to save PrEP access — and even expand it

In surprise move, FDA calls for advisory committee on Lilly's Alzheimer's drug

Apple is now the first public company to be valued at $3 trillion

Amylyx ALS drug fails large clinical trial

Over 800 arrested across France in 3rd night of riots after fatal police shooting of teen

Readout Newsletter: Bristol, Sangamo, Gilead, and more

focus

The problem with charging patients to message their doctors

UnitedHealth quietly bought dozens of outpatient centers

Steward Health Care Massachusetts hospitals face fiscal disaster

UnitedHealth quietly bought dozens of outpatient centers

Amylyx ALS drug fails trial: Relyvrio patients react with fear, worry

Ebola: Gilead Sciences antiviral shows promise as new treatment

focus

leisure time

leisure time

entertainment